ImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement Executives

CULVER CITY, Calif.- ImmunityBio, Inc. (NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced two key executive appointments that bring industry-leading market growth and access experience to the company. Helen Luu will serve as the company’s first Chief Commercial Officer, joining ImmunityBio from her position as CEO of CAR-T developer Cell BT. The company also named Sigrid Schreiner as Senior Vice President of Global Market Access.

Read the source article at businesswire.com
2021-09-07 01:00:00